Integrative Roles of Functional Foods, Microbiotics, Nutrigenetics, and Nutrigenomics in Managing Type 2 Diabetes and Obesity - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40004938/
Diabetes and obesity are globally prevalent metabolic disorders posing significant public health challenges. The effective management of these conditions requires integrated and personalized strategies. This study conducted a systematic literature...
This review explores the interplay of functional foods, gut microbiota, and nutrigenomics in managing diabetes and obesity, emphasizing personalized nutrition strategies for metabolic health and advocating further clinical validation.
Effect of dietary anthocyanins on the risk factors related to metabolic syndrome: A systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39928643/
Dietary anthocyanins effectively improve low HDL cholesterol, hypertriglyceridemia, and hyperglycemia, making them a promising adjunct for managing MetS. However, it is important to note that dietary anthocyanin interventions may raise...
Dietary anthocyanins improve HDL-C, triglycerides, and glycemic markers in MetS but show minimal effects on obesity and blood pressure. Further large-scale trials are needed to confirm long-term efficacy and safety.
LDL-cholesterol lowering agents (statins and PCSK9 inhibitors) and the risk of intracerebral hemorrhage: A network meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39755190/
LDL-Cholesterol lowering agents (statins and PCSK-9 inhibitors) was not associated with a significant increased risk of ICH. Our network meta-analysis provides strong evidence for the safety of statins and PCSK-9...
Statins and PCSK-9 inhibitors were not associated with a significant increased risk of intracerebral hemorrhage. Network meta-analysis confirms their safety, though further studies are needed for validation.
Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39176329/
Dyslipidemia refers to the change in the normal levels of one or more lipid components in the bloodstream, which include triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and...
Dyslipidemia, a key cardiovascular risk, is managed through lifestyle changes and lipid-lowering drugs like statins, fibrates, PCSK9 inhibitors, and bempedoic acid. Further trials are needed to assess efficacy and safety.
Dyslipidemia Treatment and Cerebrovascular Disease: Evidence Regarding the Mechanism of Stroke - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38826180/
Dyslipidemia stands as a significant risk factor for stroke, on par with the impact of hypertension, diabetes, and smoking. While the role of dyslipidemia is firmly established in the context...
Dyslipidemia significantly influences stroke risk, with varying impacts across stroke subtypes. This study examines lipid-lowering therapies like statins, ezetimibe, and PCSK9 inhibitors for secondary stroke prevention and dyslipidemia management.